ARCA biopharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ARCA biopharma and buy or sell other stocks, ETFs, and their options commission-free!

About ABIO

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. 

CEO
Lawrence O. Klein, PhD
CEOLawrence O. Klein, PhD
Employees
68
Employees68
Headquarters
Menlo Park, California
HeadquartersMenlo Park, California
Founded
—
Founded—
Employees
68
Employees68

ABIO Key Statistics

Market cap
214.46M
Market cap214.46M
Price-Earnings ratio
-39.44
Price-Earnings ratio-39.44
Dividend yield
—
Dividend yield—
Average volume
1.12M
Average volume1.12M
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
$115.52
52 Week high$115.52
52 Week low
$25.23
52 Week low$25.23

Stock Snapshot

With a market cap of 214.46M, ARCA biopharma(ABIO) trades at $3.19. The stock has a price-to-earnings ratio of -39.44.

On 2026-11-20, ARCA biopharma(ABIO) shares started trading at —, with intraday highs of — and lows of —.

Trading volume for ARCA biopharma(ABIO) stock has reached 0, versus its average volume of 1.12M.

Over the past 52 weeks, ARCA biopharma(ABIO) stock has traded between a high of $115.52 and a low of $25.23.

Over the past 52 weeks, ARCA biopharma(ABIO) stock has traded between a high of $115.52 and a low of $25.23.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.